COGT News and Press, Cogent Biosciences Inc Com

WALTHAM, Mass. and BOULDER, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has reached alignment with the U.S. Food and Drug Admin...

2024-06-26 16:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-23 06:18:15 ET Summary Today, we revisit clinical stage biotech firm Cogent Biosciences for the first time since 2022. The company is heading into the potential inflection year in 2025 and top line results from three late-stage trials should be out during the year. Cog...

Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions Reductions were shown in all individual MS2D2 symptoms across domains and objective reduction in skin lesions corresponding with symptomatic improvement WALT...

2024-05-24 14:09:50 ET More on Cogent Biosciences Cogent downgraded at Baird on rare disease drug data Seeking Alpha’s Quant Rating on Cogent Biosciences Historical earnings data for Cogent Biosciences Financial information for Cogent Biosciences ...

WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. ...

Bezuclastinib + sunitinib combination therapy reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior treatment Encouraging long-term safety and tolerability with combination bezuclastinib and sunitinib therapy in P...

2024-05-07 12:05:43 ET More on Cogent Biosciences Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst Cogent downgraded at Baird on rare disease drug data Cogent Biosciences stock jumps on Phase 2 data for bezuclastinib Seeking Alph...

SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 1Q 2024 with $435.7 million in cash, sufficient to fund operations into 2027 WALTHAM, Mass. and BOULDER, Colo., May 07, 2024 (GLOBE...

WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective,...